Bristol Myers Squibb seals $380M CAR-T therapy production deal

With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable

Related Keywords

Japan ,Bristol Myers Squibb ,Fabian Gerlinghaus ,Manufacturing Organization ,Cell Shuttle ,Smart Factories ,Cellare Cell Shuttle ,Integrated Development ,Cabaletta Bio ,Bio Developments ,Cell Amp Gene Therapies ,9 ,Ar T ,Cart Cell Therapy ,Ncology ,